Glecaprevir/pibrentasvir
| Combination of | |
|---|---|
| Glecaprevir | NS3/NS4A inhibitor |
| Pibrentasvir | NS5A inhibitor |
| Clinical data | |
| Trade names | Mavyret, Maviret, others |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a617039 |
| License data | |
| Pregnancy category |
|
| Routes of administration | By mouth |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| KEGG | |
Glecaprevir/pibrentasvir (G/P), sold under the brand names Mavyret and Maviret, is a fixed-dose combination medication used to treat hepatitis C.[4][5] It contains glecaprevir and pibrentasvir.[5][6] It works against all six types of hepatitis C.[4] At twelve weeks following treatment between 81% and 100% of people have no evidence of hepatitis C.[7] It is taken once a day by mouth with food.[4][5]
The most common side effects are headache, diarrhea, and tiredness.[7][8] In those with a history of hepatitis B, reactivation may occur.[8] It is not recommended in people with moderate to severe liver disease.[7] Glecaprevir works by blocking the protein NS3/4A protease, while pibrentasvir works by blocking NS5A.[4]
The combination was approved for medical use in the United States and Europe in 2017.[6][4] It is on the World Health Organization's List of Essential Medicines.[9]
- ^ "Glecaprevir / pibrentasvir (Mavyret) Use During Pregnancy". Drugs.com. 10 October 2019. Retrieved 30 March 2020.
- ^ "Liver disease". Health Canada. 9 May 2018. Retrieved 13 April 2024.
- ^ "Maviret 100 mg/40 mg Film-coated Tablets - Summary of Product Characteristics (SmPC)". (emc). 11 March 2020. Retrieved 30 March 2020.
- ^ a b c d e "Maviret EPAR". European Medicines Agency (EMA). 17 August 2017. Retrieved 30 March 2020.
- ^ a b c Cite error: The named reference
Mavyret FDA labelwas invoked but never defined (see the help page). - ^ a b "FDA approves Mavyret for Hepatitis C" (Press release). U.S. Food and Drug Administration (FDA). 3 August 2017. Archived from the original on 1 December 2019.
- ^ a b c "FDA approves treatment for adults and children with all genotypes of hepatitis C and compensated cirrhosis that shortens duration of treatment to eight weeks". U.S. Food and Drug Administration (FDA). 26 September 2019. Archived from the original on 27 September 2019. Retrieved 1 October 2019.
- ^ a b British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. p. 620. ISBN 9780857113382.
- ^ World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.